AIP
AXSM icon

Arrowpoint Investment Partners’s Axsome Therapeutics AXSM Stock Holding History

Arrowpoint Investment Partners’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.77M Buy
16,401
+14,291
+677% +$2.47M 2.46% 9
2025
Q4 		$385K Buy
+2,110
New +$295K 0.06% 81

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Arrowpoint Investment Partners's AXSM Position: Q1 2026 in Review

Arrowpoint Investment Partners increased its Axsome Therapeutics (AXSM) stake by 677% in Q1 2026, buying an estimated $2.47M and bringing the position to 16,401 shares worth $2.77M. The position accounts for 2.46% of the portfolio, ranked #9.

Arrowpoint Investment Partners first reported a position in AXSM in Q4 2025 and has held it in 2 quarters since. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Arrowpoint Investment Partners held 16,401 shares of Axsome Therapeutics worth $2.77M as of Q1 2026.
  • Arrowpoint Investment Partners bought 14,291 Axsome Therapeutics shares in Q1 2026, an estimated $2.47M.
  • Axsome Therapeutics made up 2.46% of Arrowpoint Investment Partners's portfolio in Q1 2026, its #9 holding.
  • Arrowpoint Investment Partners first reported a position in Axsome Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Arrowpoint Investment Partners's 13F filing for Q1 2026, filed 14 May 2026.